Cardiomyopathy

3 articles published between September 23, 2025 and August 30, 2026.

Covered in Global Health, Sports & Performance and Science.

Africa's largest acute heart failure study finds a median patient age of 56

THESUS-HF II enrolled 1,578 patients across 50 hospitals in 17 countries. Guideline drugs were prescribed at discharge in most patients, and target doses were reached in fewer than half.

4 min read

ANALYSIS

Bodybuilding's richest season yet, and the mortality data running beneath it

The 2026 Arnold Classic paid a record $750,000. Two European Heart Journal cohorts covering 29,733 IFBB competitors put sudden cardiac death rates far above what athlete screening programmes usually report.

5 min read

THE DRUG DOCKET

FDA clears the first drug for Barth syndrome, four months after rejecting it

Forzinity was approved under accelerated approval to improve muscle strength in patients weighing at least 30 kg. The confirmatory trial is not due to report until 2030.

4 min read

This page indexes this newspaper’s reporting on Cardiomyopathy. It is not a medical reference entry, and nothing here is medical advice. See our editorial standards.